Literature DB >> 1464276

Carbamazepine (CBZ) controlled release compared with conventional CBZ: a controlled study of attention and vigilance in children with epilepsy.

M S Pieters1, A Jennekens-Schinkel, T Stijnen, P M Edelbroek, O F Brouwer, L Liauw, A Heyer, J B Lanser, A C Peters.   

Abstract

To compare the effects on attention and vigilance of conventional carbamazepine (CBZ) and CBZ controlled release (CBZ-CR), 15 schoolchildren with epilepsy and normal intelligence receiving CBZ were switched to CBZ-CR. Psychological examination was performed on the day before (day A) and 1 month after substitution (day B). Measurements of attention and vigilance were repeated throughout the day at 2-h intervals. Both on days A and B, CBZ plasma levels were monitored during a 12-h period. Fifteen matched healthy controls were submitted to identical test programs, allowing comparisons within subjects as well as between patients and control children. Variability of performance over sessions was neither increased nor decreased with CBZ-CR. Consistent differences over sessions did not exist between patients and controls with either drug. No relation was noted between reaction time and CBZ plasma level. The pharmacologic data confirm results of earlier studies in children. We noted a reduction in intradose fluctuations of CBZ level with CBZ-CR as compared with conventional CBZ. The neuropsychological results do not show a difference between the drugs. Neither were differences noted with respect to antiepileptic efficacy and side effects. At the end of the study, all but one of the children (and their parents) opted to receive CBZ-CR for ease of dosage administration and overall satisfaction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464276     DOI: 10.1111/j.1528-1157.1992.tb01771.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  5 in total

Review 1.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

2.  Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.

Authors:  P J McKee; J Blacklaw; A Carswell; R A Gillham; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

Review 3.  Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors.

Authors:  Marco Mula; Michael R Trimble
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 4.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 5.  Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.

Authors:  Graham Powell; Matthew Saunders; Alexandra Rigby; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.